Clinical Trials

Find a Clinical Trial

Enrolling Trials

151-160  of  168
►
CIRB, A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Lung
Adult
This phase II Lung-MAP non-Match treatment trial studies how well ramucirumab and pembrolizumab work versus standard of care in treating patients with non-small cell lung cancer that is stage IV or has come back. Immunotherapy with monoclonal antibodies, such as ramucirumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in standard of care chemotherapy for non-small cell lung cancer, such as docetaxel, gemcitabine hydrochloride, and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ramucirumab and pembrolizumab together may work better in treating patients with non-small lung cancer compared to standard of care.
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI 54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
MMC - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - River Region at Stevens Point
4100 State Highway 66
Stevens Point, WI 54482
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476
►
CIRB, A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma
Melanoma
Adult
This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery may work better in treating melanoma.
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Eau Claire
2310 Craig Rd
Eau Claire, WI 54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI 54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
MMC - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - River Region at Stevens Point
4100 State Highway 66
Stevens Point, WI 54482
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476
►
CIRB, Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Dental
Genitourinary
Adult
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading. standard systemic therapy alone.
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MMC - Eau Claire
2310 Craig Rd
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
MMC - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - River Region at Stevens Point
4100 State Highway 66
Stevens Point, WI 54482
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476
zzzDiagnostic & Treatment Center
3401 CRANBERRY BLVD
WESTON, WI 54476
►
CIRB, A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Gastro-Intestinal (GI)
Adult
This phase III trial studies how well gemcitabine hydrochloride and cisplatin given with or without nab-paclitaxel work in treating patients with newly diagnosed biliary tract cancers that have spread to other places in the body. Drugs used in chemotherapy, such as gemcitabine hydrochloride, cisplatin, and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not known if giving gemcitabine hydrochloride and cisplatin with or without nab-paclitaxel may work better at treating biliary tract cancers.
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Eau Claire
2310 Craig Rd
Eau Claire, WI 54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI 54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
MMC - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - River Region at Stevens Point
4100 State Highway 66
Stevens Point, WI 54482
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476
►
CIRB, A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Lung
Adult
Primary Objectives: To evaluate the overall response rate (ORR) (confirmed and unconfirmed, complete and partial) associated with rucaparib in patients with genomic LOH high and/or deleterious BRCA1/2 mutations within:Cohort 1: Patients with squamous cell histology or mixed histology with a squamous component. Cohort 2: Patients with non-squamous histology (adenocarcinoma, large cell, or NSCLC NOS)
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MC - Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI 54401
MC - Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI 54494
MMC - Eau Claire
2310 Craig Rd
Eau Claire, WI 54701
MMC - Ladysmith
906 College Ave W
Ladysmith, WI 54848
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
MMC - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - River Region at Stevens Point
4100 State Highway 66
Stevens Point, WI 54482
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476
►
WIC - Establishment of a WI Site for the Centers for Autism and Developmental Disabilities Research and Epidemiology (CADDRE)
This proposal seeks to establish for the first time in Wisconsin a recruitment, data collection and collaborative research site within the CDC¿s multi-site Study to Explore Early Development (SEED) of autism spectrum disorder (ASD). The overall goals of the SEED are to: characterize phenotypic variability and identify relatively homogeneous subgroups of ASD; and investigate risk factors for ASD by comparing the early exposures and development of well-characterized ASD cases and controls selected to represent diverse population subgroups.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
►
ICH- The AMPLATZER Post-infarct Muscular VSD Occluder Humanitarian Device Exemption (H070005) Post Approval Study
Cardiology
Adult
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
►
Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection
Lymphoma
Miscellaneous Neoplasm
Rare Tumors
Adult
Primary Objective: To assess the benefit of docetaxel as measured by improvement in freedom from progression (phase II) and subsequently metastasis free survival (phase III) when given in combination with radiation and androgen deprivation in treatment of high risk prostate cancer post-radical prostatectomy.
MC - Chippewa Falls Center
2655 CTY HWY I
CHIPPEWA FALLS, WI 54729
MMC - Eau Claire Cancer Center
2200 Craig Road
Eau Claire, WI 54701
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
MMC - Minocqua
9576 Highway 70
MINOCQUA, WI 54548
MMC - Rice Lake
1700 W STOUT ST
RICE LAKE, WI 54868
MMC - Weston
3400 Ministry Parkway
WESTON, WI 54476
►
Assessment of DHA On Reducing Early Preterm Birth (ADORE Trial)
Docosahexaenoic acid (DHA) is a nutrient found in some fish and eggs and its intake in US diets is typically low. Because DHA is important for early brain development, it has recently been added to many prenatal supplements. The usual amount is around 200 mg/day. Participants in this study are guaranteed to receive at least 200 mg/day of DHA. Almost 5 in 100 births in the US occur before 34 weeks of pregnancy. There is no way to predict which births will occur before 34 weeks. In an earlier study conducted at the University of Kansas Medical Center, women who received 600 mg DHA/day compared to no DHA had fewer births before 34 weeks of pregnancy with fewer complications of preterm birth. This study is designed to compare standard care (200 mg/day of DHA) to a higher amount of DHA (1000 mg/day) to determine if the higher amount will reduce early preterm birth (birth before 34 weeks of pregnancy). Individual participation in this study is expected last about 5 months.
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449
►
qatest1
ct.govtest1
MMC - Marshfield
1000 N OAK AVE
MARSHFIELD, WI 54449